{"brief_title": "Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC", "brief_summary": "To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prevention of oral candidiasis in patients with AIDS or AIDS related complex (ARC) (group III or IV, CDC classification).", "condition": ["Candidiasis, Oral", "HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Nystatin"], "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Systemic or oral antibiotics. - Experimental drugs (IND drugs) which are targeted specifically against the AIDS (group IV CDC classification) virus or stimulate the immune system. Patients with the following conditions are included: - AIDS or AIDS related complex (ARC) (HIV infection Group 3 or 4, CDC classification) who have had culture-proven oral candidiasis clinically cured within 7 days of study entry and are likely to be compliant for the 20 weeks of nystatin pastille prophylaxis. - Able to follow instructions regarding the use of a pastille. - Patients entering part II of this study (randomized double-blind) must have been clinically cured of oral candidiasis within 1 - 7 days of entry into this randomized study. - Oral lesions such as Kaposi's sarcoma, herpes zoster, and herpes simplex can be enrolled. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Systemic candidiasis. - Hypersensitivity to nystatin. - Suspected or proven candidal esophagitis. Patients with the following are excluded: - Systemic candidiasis. - Projected survival of less than 6 months. - Unable to maintain a pastille in the buccal cavity for approximately 20 minutes twice a day. - Hypersensitivity to nystatin. - Suspected or proven candidal esophagitis.", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Candidiasis, Oral", "mesh_term": ["HIV Infections", "Candidiasis", "Candidiasis, Oral", "Nystatin"], "id": "NCT00002057"}